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Abstract
Introduction: The aim of this study was to assess pneumatic tube system (PTS) alteration on platelet function by the light transmission aggrego-
metry (LTA) and whole blood aggregometry (WBA) method, and on the results of platelet count, prothrombin time (PT), activated partial throm-
boplastin time (APTT), and fibrinogen.
Materials and methods: Venous blood was collected into six 4.5 mL VACUETTE® 9NC coagulation sodium citrate 3.8% tubes (Greiner Bio-One 
International GmbH, Kremsmünster, Austria) from 49 intensive care unit (ICU) patients on dual anti-platelet therapy and immediately hand carried 
to the central laboratory. Blood samples were divided into 2 Groups: Group 1 samples (N = 49) underwent PTS (4 m/s) transport from the central 
laboratory to the distant laboratory and back to the central laboratory, whereas Group 2 samples (N = 49) were excluded from PTS forces. In both 
groups, LTA and WBA stimulated with collagen, adenosine-5’-diphosphate (ADP), arachidonic acid (AA) and thrombin-receptor-activated-peptide 6 
(TRAP-6) as well as platelet count, PT, APTT, and fibrinogen were performed. 
Results: No statistically significant differences were observed between blood samples with (Group 1) and without (Group 2) PTS transport (P values 
from 0.064 – 0.968). The AA-induced LTA (bias: 68.57%) exceeded the bias acceptance limit of ≤ 25%.
Conclusions: Blood sample transportation with computer controlled PTS in our hospital had no statistically significant effects on platelet aggrega-
tion determined in patients with anti-platelet therapy. Although AA induced LTA showed a significant bias, the diagnostic accuracy was not influen-
ced. 
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Platelets play a key role in primary hemostasis. The 
principal function is stopping hemorrhage and 
preventing blood loss, when vessel walls are in-
jured (1). Platelets interacting with the exposed 
matrix adhere, become activated, and as a conse-
quence bind further platelets to form a thrombus 
limited in size. Specific platelet receptors are in-
volved in each of these phases (2).
Platelet function testing has become essential for 
identifying patients with platelet dysfunction and 
for monitoring modern anti-platelet therapy. In 
hemostasis laboratories, platelet aggregometry 
has been established one of the most widely used 
platelet function testing procedures (3). Light 
transmission aggregometry (LTA), which was de-
veloped in 1962 by Born and O’Brien, and imped-
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ance whole blood aggregometry (WBA) are the 
two main types of methodologies available (3-6).
Since platelets are sensitive to artificial manipula-
tion, preanalytical variables may influence hemo-
stasis testing in laboratories. The tourniquet appli-
cation time is reported biasing platelet function 
testing by multiple electrode aggregometry (MEA) 
(Multiplate®) (7). Moreover, in clinical routine labo-
ratories different vacuum tubes may represent a 
relevant source of variability on the determination 
of the mean platelet volume and platelet distribu-
tion width (8). Recently, one study concluded that 
physical exercise in cold water also represents a 
stress factor, which may cause increased platelet 
counts (9). Preanalytical variables are often outside 
the control of hemostasis laboratories and the 
leading causes of diagnostic error (10). Several cru-
cial steps in the preanalytical phase, such as cor-
rect blood collection, blood sample handling, 
transport and storage of specimens are essential 
parts to get valid and timely laboratory test results 
(11).
Over the last years, in many hospitals pneumatic 
tube systems (PTS) have been established for 
blood sample transport between departments 
and outpatient clinics. PTS is considered an effi-
cient and cost effective transport solution special-
ly designed to handle automated blood specimen 
transport in routine and emergency settings. Nev-
ertheless, blood samples transported by PTS are 
often subjected to high speed (up to 7.6 m/s) ac-
companied by rapid acceleration and deceleration 
causing shear stress (12). Changes in air pressure, 
vibrations and shaking of blood samples are con-
sidered to affect various laboratory parameters in-
cluding coagulation assays (13).
In the literature, various studies have been per-
formed on the effects of PTS on popular point-of-
care thromboelastometry (ROTEM®) analysis. A 
study by Amann et al. including 20 healthy volun-
teers reported statistically significant changes (P 
values < 0.001) in multiple ROTEM® parameters 
transported by PTS (14). In contrast, Colucci et al. 
observed no statistically significant differences (P 
values from 0.381 – 0.978) between pneumatic de-
livery and hand carried transport in 30 whole 
blood samples of healthy volunteers (15). While 
study results of PTS effects on ROTEM® analyses 
are discordant, only few data are available about 
platelet alteration after blood sample transporta-
tion with PTS on LTA and WBA, respectively. An 
overview on previously published original re-
search articles investigating PTS effects on platelet 
function testing is given in Table 1.
The aim of the present study was to investigate 
the effect of PTS on the results of LTA, WBA, plate-
let count, prothrombin time (PT), activated partial 
thromboplastin time (APTT), and fibrinogen.
Table 1. Previously published original research articles investigating pneumatic tube system effects on platelet function testing
Year Author Journal Subjects, N Methods PTS effect Reference





2005 Walin et al. CCLM 28 PFA-100TM No effect 19
2009 Bollinger et al. Platelets 50 Multiplate® Aggregation ↓ 20









EXTEM CT ↑ 22
2013 Thalén et al. Thromb Res 58 Multiplate® Aggregation ↓ 23
JTH – Journal of Thrombosis and Haemostasis. CCLM – Clinical Chemistry and Laboratory Medicine. Clin Lab – Clinical Laboratory. 
Thromb Res – Thrombosis Research. PFA – platelet function analyzer. CADP – collagen membrane coated with ADP. WBA – whole 
blood aggregometry. Ω – impedance. LTA – light transmission aggregometry. ROTEM – rotational thrombelastometry. EXTEM – 
extrinsic rotational thrombelastometry. CT – clotting time. ↑ – increased. ↓ – decreased.
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Materials and methods
Subjects
This experimental study was conducted at the 
Medical University of Graz (Graz, Austria). The 
study period was from 01th January to 31th De-
cember 2008. A total of 49 patients from the Inten-
sive Care Unit (ICU) of the Department of Anesthe-
siology and Intensive Care Medicine, who were on 
full dual anti-platelet drug therapy with 100 mg 
acetyl-salicylate acid and 75 mg clopidogrel daily, 
were included. Thirty-six (0.74) patients were male 
and 13 (0.26) were female. The median age was 65 
(range: 47 – 89) years. This study was carried out in 
accordance with the latest version of the Declara-
tion of Helsinki given by the World Medical Asso-
ciation. The ethical approval was provided by the 
Ethical Committee of the Medical University of 
Graz (Graz, Austria). All study subjects gave written 
informed consent for participation in the study.
Blood sampling
Blood sampling was done in the morning without 
obligatory fasting state. From all 49 study partici-
pants venous blood was collected into six 4.5 mL 
VACUETTE® 9NC coagulation sodium citrate 3.8% 
tubes (Greiner Bio-One International GmbH, 
Kremsmünster, Austria). Immediately after the 
venipuncture, all vacuum tubes (6 x 49) were gen-
tly inverted five times and hand carried by our lab-
oratory personal to the core laboratory of our hos-
pital. In the central laboratory blood samples were 
divided in Group 1 (3 x 49 tubes) and Group 2 (3 x 
49 tubes) without delay. Group 1 blood samples 
were transported with the PTS from the central 
laboratory to the distant laboratory and returned 
again with the PTS from the distant laboratory to 
the central laboratory. Group 2 blood samples 
were excluded from PTS transport.
After transport all collected blood samples stored 
30 minutes at room temperature. The original vac-
uum tubes 1 (Group 1 and Group 2) were gently 
inverted 5 times and 8 x 450 µL were pipetted in 
duplicates in each channel of a 4 channel 
Chronolog 700 Aggregometer (Chronolog Corpo-
ration, Havertown, Pennsylvania, USA) to perform 
impedance WBA. The original vacuum tubes 2 and 
3 (Group 1 and Group 2) were centrifuged at 110 x 
g for 15 minutes at room temperature to obtain 
platelet rich plasma (PRP), using a GS-15 centrifuge 
(Beckman Coulter GmbH, Vienna, Austria). The PRP 
was removed from tubes 2 and 3 and mixed in 15 
mL Eppendorf Conical Tubes® (Eppendorf Austria 
GmbH, Vienna, Austria) for further analysis. From 
the Eppendorf Conical Tubes®, 8 x 450 µL were pi-
petted in duplicates in each channel of a 4 channel 
Chronolog 700 Aggregometer (Chronolog Corpo-
ration, Havertown, Pennsylvania, USA) to perform 
LTA. Platelet count was performed from PRP on the 
Sysmex XE-2100TM Automated Hematology System 
(Sysmex Austria GmbH, Vienna, Austria). Approxi-
mately 2.7 mL blood was left in each of the original 
vacuum tubes 2 and 3 (Group 1 and Group 2), which 
were centrifuged once more at 2800 x g for 15 min-
utes at room temperature to obtain platelet poor 
plasma (PPP). PPP was used for PT, APTT and fibrin-
ogen measurements and for blank value determi-
nations of the aggregometer.  
Methods
Pneumatic tube system (PTS)
Blood samples of Group 1 (3 x 49 tubes) were 
transported by a computer controlled PTS (Swiss-
log Rohrpostsysteme GmbH, Westerstede, Germa-
ny) using standard pneumatic tube carriers. One 
distance was about 500 m with a mean transit 
time of 2 min. As a result Group 1 samples (3 x 49 
tubes) were subjected a twice done acceleration 
and deceleration during transportation process 
with PTS, whereas Group 2 samples (3 x 49 tubes) 
were excluded from PTS transport.
After computer controlled acceleration an average 
velocity of 4m/s was used. Special receiving stations 
with controlled deceleration delivered softly the 
pneumatic tube carrier on special exit conveyor belts.
Light transmission aggregometry (LTA)
LTA was performed in duplicates using a 4 channel 
Chronolog 700 Aggregometer (Chronolog Corpo-
ration, Havertown, Pennsylvania, USA). After pipet-
ting 450 µL PRP in each channel, aggregation was 
induced using final concentrations of 2 µg/mL col-
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lagen (Chronolog Corporation, Havertown, Penn-
sylvania, USA), 10 µmol/L adenosine 5’-diphos-
phate (ADP) (Sigma-Aldrich Handels GmbH, Vien-
na, Austria), 0.5 mmol/L arachidonic acid (AA) 
(Chronolog Corporation, Havertown, Pennsylva-
nia, USA), and 40 µmol/L thrombin receptor-acti-
vated peptide 6 (TRAP-6) (Bachem Distribution 
Services GmbH, Weil/Rhein, Germany). Light trans-
mission (% aggregation and area under the curve 
(AUC)) was measured in Group 1 and 2 and com-
pared statistically. A maximal amplitude of < 5% 
and an AUC of < 75 were interpreted as total inhi-
bition of platelet function depending on the 
above mentioned platelet aggregation inducing 
reagents. Daily quality control (QC) measurements 
were performed with normal plasma of healthy 
volunteers. Coefficients of variation (CV) for light 
transmission % and AUC were as follows: collagen 
- 4.01 and 3.18%, respectively; ADP - 3.38 and 
6.53%, respectively; AA - 2.19 and 4.94%, respec-
tively; TRAP - 4.14 and 2.5%, respectively.
Impedance whole blood aggregometry (WBA) 
Impedance WBA was performed in duplicates us-
ing a 4 channel Chronolog 700 Aggregometer 
(Chronolog Corporation, Havertown, Pennsylvania, 
USA). After pipetting 450 µL whole blood in each 
channel, aggregation was induced with the same 
agents and final concentrations as described above. 
The impedance (Ω and AUC) was measured in 
Group 1 and 2 samples and compared statistically. 
A maximal impedance of < 0.5 Ω and an AUC of < 5 
and were interpreted as total inhibition of platelet 
function depending on the above mentioned plate-
let aggregation inducing reagents. Daily QC meas-
urements were performed with normal plasma of 
healthy volunteers. Coefficients of variation for im-
pedance Ω and AUC were as follows: collagen - 
4.06 and 10.9%, respectively; ADP - 13.47 and 
12.38%, respectively; AA - 13.72 and 8.72%, respec-
tively; TRAP - 12.06 and 10.52%, respectively.
Coagulation parameters
The number of platelets was determined on the 
Sysmex XE-2100TM Automated Hematology Sys-
tem (Sysmex Austria GmbH, Vienna, Austria). The 
PT (Thromborel® S reagent, Siemens Healthcare Di-
agnostics GmbH, Vienna, Austria), APTT (Pathrom-
tin® SL reagent, Siemens Healthcare Diagnostics 
GmbH, Vienna, Austria), and fibrinogen (Multifi-
bren® U reagent, Siemens Healthcare Diagnostics 
GmbH, Vienna, Austria) were measured on the Sie-
mens/Dade Behring BCS XP Analyzer Automated 
Coagulation System (Siemens Healthcare Diagnos-
tics GmbH, Vienna, Austria). Daily QC measure-
ments were performed with commercially available 
control material within the normal and pathological 
ranges (Control Plasma N and P (Siemens Health-
care Diagnostics GmbH, Vienna, Austria): PT 73.0 - 
109.0 % and 32 - 48 %; APTT 28.0 - 38.0 s and 70 - 
105 s; fibrinogen 2.2 - 3.2 g/L and 0.6 - 1.4 g/L, re-
spectively; e-CHECK®(XE) (Sysmex Austria GmbH): 
platelet counts 195 – 240 G/L, 30 – 75 G/L and 480 - 
580 G/L). Inter-assay precision was calculated with 
results of minimum 20 consecutive days. One ten-
fold measurement was performed at one day to de-
termine the intra-assay precision. The intra- and 
inter-assay CV were as follows: for PT 1.71 and 
3.26%, respectively; for PT-INR 2.43 and 3.24%, re-
spectively; for APTT 2.31 and 2.83%, respectively; 
for fibrinogen 1.23 and 2.87%, respectively; and 
for platelet count 1.23 and 3.4%, respectively. 
Statistical analysis
The distribution of data was calculated with the 
Kolmogorov-Smirnov test. The non-parametric Wil-
coxon test was used for comparisons of parameters 
between Group 1 and Group 2. Not normally dis-
tributed data were described in medians (Q1 – Q3). 
A P-value < 0.05 was considered statistically signifi-
cant. Bias calculation was performed and compared 
with available acceptance criteria in accordance 
with the Milano hierarchy (16). The calculated biases 
were compared to the acceptance limits based on 
the Clinical Laboratory Improvement Amendments 
(CLIA) for analytical quality (17). SPSS Statistics for 
Windows version 22.0 (IBM SPSS Inc., Chicago, Illi-
nois, USA) was used for statistical analysis. 
Results 
The results of platelet function testing with LTA 
and WBA, and the coagulation parameters (i.e., 
platelet count, PT, APTT, and fibrinogen) between 
blood samples of Group 1 (N = 49) and Group 2 (N 
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= 49) and the mean bias are shown in Table 2. All 
parameters investigated in the present study were 
not normally distributed and are presented in me-
dians (Q1 – Q3). No statistically significant differ-
ences were observed between blood samples 
transported with (Group 1) and without PTS 
(Group 2) (P values from 0.064 – 0.968).
Discussion
To the best of our knowledge, this is the first study 
reporting data about PTS effects on both, optical 
aggregometry as well as impedance aggregrome-
try measurements in patients on anti-platelet drug 
therapy. The results referred only to patients on 
dual acetyl-salicylate acid and clopidogrel therapy 




P value Bias (%) Bias criteria 
(%) 
Collagen-induced % 28.0 (16.8 – 47.0) 28.5 (14.0 – 50.0) 0.592 1.75 ≤ 25
AUC 222.2 (112.1 – 337.1) 227.7 (99.3 – 376.4) 0.682 2.42 ≤ 25
ADP-induced % 33.0 (24.0 – 40.8) 35.5 (21.0 – 43.0) 0.406 7.04 ≤ 25
AUC 280.8 (138.6 – 338.6) 279.9 (127.2 – 362.4) 0.568 0.32 ≤ 25
AA-induced % 2.0 (1.0 – 11.0) 2.0 (1.0 – 16.3) 0.741 0.0 ≤ 25
AUC 23.6 (0.25 – 51.35) 14.0 (0.0 – 52.5) 0.064 68.57 ≤ 25
TRAP-6-induced % 51.0 (35.0 – 59.0) 52.0 (43.5 – 62.0) 0.141 1.92 ≤ 25
AUC 441.6 (290.6 – 512.8) 438.6 (348.3 – 521.4) 0.915 0.68 ≤ 25
WBA
Collagen-induced Ω 8.0 (5.0 – 11.0) 8.0 (4.0 – 12.0) 0.444 0.0 ≤ 25
AUC 44.8 (18.8 – 66.1) 40.1 (18.6 – 74.9) 0.165 11.72 ≤ 25
ADP-induced Ω 2.0 (0.0 – 5.3) 2.5 (1.0 – 7.0) 0.180 20.0 ≤ 25
AUC 8.55 (0.0 – 31.6) 11.0 (0.0 – 42.5) 0.361 22.27 ≤ 25
AA-induced Ω 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 0.549 0.0 ≤ 25
AUC 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 0.286 0.0 ≤ 25
TRAP-6-induced Ω 3.0 (1.0 – 9.0) 3.0 (1.0 – 9.0) 0.733 0.0 ≤ 25




x 109/L 94.0 (66.0 – 142.0) 94.0 (66.0 – 139.0) 0.418 0.0 ≤ 25
x 109/L 175.0 (114.0 – 267.0) 170.0 (123.0 – 267.0) 0.176 2.94 ≤ 25
PT INR 1.1 (1.0 – 1.3) 1.1 (1.0 – 1.3) 0.968 0.0 ≤ 15
% 91.0 (72.0 – 107.0) 92.0 (75.0 – 107.0) 0.909 1.09 ≤ 15
APTT s 42.4 (38.3 – 49.8) 43.5 (38.3 – 49.7) 0.426 2.53 ≤ 15
Fibrinogen g/L 6.3 (3.6 – 7.9) 6.1 (3.6 – 8.0) 0.726 3.30 ≤ 20
LTA - light transmission aggregometry. WBA - whole blood aggregometry. Ω – impedance. Group 1 – blood samples transported 
with pneumatic tube system (PTS). Group 2 – blood samples transported without PTS. ADP – adenosine diphosphate. AA – 
arachidonic acid. TRAP-6 – thrombin receptor-activated peptide 6. AUC – area under the curve. WB – whole blood. PRP – platelet 
rich plasma. PT – prothrombin time. INR – international normalized ratio. APTT – activated partial thromboplastin time. Differences 
between Group 1 and Group 2 were evaluated using the Wilcoxon test. Data are presented as medians (Q1 – Q3). P < 0.05 was 
considered statistically significant. Bias criteria according to reference 17.
Table 2. Light transmission, impedance and coagulation parameters
Biochemia Medica 2017;27(1):217–24  http://doi.org/10.11613/BM.2017.023 
222
Enko D. et al. Transport effects on platelet function
and not on healthy individuals. Overall 49 study 
participants were included in this experimental 
study. 
In comparison, previously published studies on 
the subject of PTS effects on platelet aggregation 
tests were designed with 12 to 58 subjects (18 - 23) 
(Table 1). Two studies, comprising 58 and 50 indi-
viduals, observed significant influence on imped-
ance WBA with a Multiplate® analyzer (20,23). In 
both studies, detailed information about speed of 
sample transport and other characteristics of the 
PTS, that may strongly affect pre-analytical quality 
are lacking. Reducing speed is considered to avoid 
pre-analytical alteration of blood samples (24). 
However, different PTS configurations could be a 
potential reason for various results and observa-
tions of published data.
In the present study both methodologies, namely 
LTA as well as WBA were performed to study PTS 
effects on platelet function. These methods are 
usually performed in specialized clinical hemosta-
sis laboratories. Beside these traditional tests, pre-
viously published studies about PTS effects on 
platelet function used especially modern commer-
cially available point-of-care testing methods, such 
as the multichannel WBA with Multiplate® system 
or the relatively simple PFA-100TM technology, 
measuring platelet aggregation as a function of 
the time it takes to occlude the aperture (25).
Poor correlation among different platelet function 
testing modalities may be one limitation in com-
parison and clinical interpretation of different 
study results. Moreover, different agonists are 
used to induce platelet aggregation. Herein we 
used the aggregation agonists collagen (2 µg/mL), 
ADP (10 µmol/L), AA (0.5 mmol/L), and TRAP-6 (40 
µmol/L) with final concentrations as recommend-
ed by the manufacturer. In comparison Dyszkie-
wicz-Korpanty et al. recruited 27 healthy volun-
teers and used collagen (2 µg/mL), ADP (10 µmol/L) 
and AA (0.5 mmol/L) to perform impedance WBA 
(18), whereas Hübner et al. recruited 15 healthy 
subjects and used collagen (2 µg/mL and 5 µg/
mL), ADP (10 µmol/L) and ristocetin (1.25 g/L) to 
perform optical LTA (20). One previously published 
study about PTS effects on the Multiplate® system 
was performed with 58 individuals (32 healthy in-
dividuals, 14 patients with cardiovascular disease 
treated with aspirin and/or clopidogrel, 8 patients 
from an ICU, and 4 patients from a coagulation 
clinic) using final concentrations of 0.0032 µg col-
lagen, 0.0065 µmol ADP, 0.4839 µmol AA, 0.3076 
µg ristocetin and 0.0322 µmol TRAP in each corre-
sponding well (23). Another study on the Multi-
plate® system evaluated 50 patients with acetyl-sa-
licylate acid therapy using AA (0.5 mmol/L) and 
TRAP (32 µmol/L) only (20).
Considering these various study designs per-
formed with different agonists and concentra-
tions, the major limitation of data comparison is 
the lack of standardization in platelet function 
testing. Widespread accepted uniform guidelines 
on how laboratories should perform clinical test-
ing for disorders of platelet function are still not 
available (26,27). Results of two surveys of the 
North American Specialized Coagulation Labora-
tory Association (NASCOLA) demonstrated that 
agonist concentrations varied widely and that var-
ious methods were used to obtain reference inter-
vals for platelet aggregation testing (26). Although 
LTA is considered to be the “gold standard” for in 
vitro platelet function testing in both clinical and 
research laboratories, no evidence-based guide-
lines for the performance and interpretation of 
studies with this technique are established yet 
(28,29). Moreover no proper commercial controls 
are available for the different platelet function as-
says to examine the validity of the test results. 
In the present study the mean bias of the investi-
gated parameters between blood samples trans-
ported with (Group 1) and without PTS (Group 2) 
ranged from 0.0 to 68.57%. Compared to the avail-
able acceptance criteria in accordance with the 
Milano hierarchy (16,17), analytical performance 
evaluation studies may be influenced by the meas-
urement quality, the actual test method used, and 
the investigated study population. Therefore 
standardized platelet function testing procedures 
with commercially available QC material for LTA 
and WBA is required in order to improve analytical 
quality and reproducibility.
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The major limitation of this study is that healthy 
subjects, who were not on anti-platelet therapy, 
were not included. We cannot omit a protective 
effect on acetyl-salicylate acid and clopidogrel 
during transportation. Nevertheless, the added 
value of this study is that potential PTS effects 
were investigated on platelet function testing with 
the LTA as well as the WBA method.
In conclusion, blood sample transportation with 
soft motion computer controlled PTS, as installed 
in our hospital, had no statistically significant ef-
fects on platelet aggregation measured with opti-
cal and impedance aggregometry in patients with 
dual anti-platelet therapy. Although AA induced 
LTA showed a significant bias, the diagnostic accu-
racy was not influenced at all. Further investiga-
tion on healthy subjects without anti-platelet ther-
apy should be performed.
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